{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-015304","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.786497+00:00","generated_at":"2026-06-16T00:03:31.012662+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Elite Pharmaceuticals appoints Mark Pellegrino as CFO effective May 1, 2023","bullets":["Mark Pellegrino appointed CFO, replacing Robert Chen, effective May 1, 2023.","Annual base salary of $230,000; eligible for 1.5M stock options vesting over 3 years.","Pellegrino has 30+ years of life sciences finance experience, most recently consultant at Barbera & Barbera.","Stock option strike price set at closing price on first day of employment (ELTP)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-015304","json":"https://secwatch.observer/filing/0001493152-23-015304.json","markdown":"https://secwatch.observer/filing/0001493152-23-015304.md","text":"https://secwatch.observer/filing/0001493152-23-015304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223015304/0001493152-23-015304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223015304/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:03:31.012662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"076a8ce477","claim":"Robert Chen departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.","evidence_excerpt":"On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223015304/0001493152-23-015304-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1350fae565","claim":"Mark Pellegrino was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.","evidence_excerpt":"On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223015304/0001493152-23-015304-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}